MI GPSai™
Genomic Prevalence Score

MI GPSai™, from Caris Life Sciences®, provides a cancer type similarity assessment which compares the characteristics of a patient's tumor against other tumors in the Caris database.

MI GPSai™ analyzes a tumor's molecular signature and provides the prevalence of that signature in the Caris genomic (DNA) and transcriptomic (RNA) database across 21 cancer categories. This new tool is intended to provide additional insight to help oncologists better manage cancers of unknown primary (CUP) or cases with atypical clinical presentation or clinical ambiguity, as identified by the ordering physician.

MI GPSai™ can be added to any solid tumor order by selecting the appropriate box on the Caris requisition. Results for MI GPSai™ will be presented in the final Caris report. These results will provide additional insight by assessing how closely tumors match the genomic and transcriptomic signatures of 21 distinct cancer types to help you make more informed treatment decisions.

Example Caris Report: GPS (Genomic Prevalence Score)

Cancer Category	Prevalence
Lung Adenocarcinoma	93 %
Squamous Cell Carcinoma	5 %
Gastroesophageal Adenocarcinoma	1 %
Breast Adenocarcinoma	<1 %
Cholangiocarcinoma	<1 %
Pancreas Adenocarcinoma	<1 %
Central Nervous System Cancer	0 %
Cervical Adenocarcinoma	0 %
Colon Adenocarcinoma	0 %
GIST	0 %
Hepatocellular carcinoma	0 %
Melanoma	0 %
Meningioma	0 %
Ovarian, Fallopian Tube Adenocarcinoma	0 %
Ovarian Granulosa Cell Tumor	0 %
Prostate Adenocarcinoma	0 %
Renal Cell Carcinoma	0 %
Thyroid Cancer	0 %
Urothelial Carcinoma	0 %
Uterine Endometrial Adenocarcinoma	0 %
Uterine Sarcoma	0 %

For illustrative purposes only, not for clinical use.

- **GPS provides information on the cancer anatomic site of origin – in addition to the biomarker data from MI profiling – to guide more precise and personalized treatment options**

- **Dynamic, sliding scale prevalence score to improve readability and interpretation**

- **Cancer categories are ranked by prevalence score and then alphabetized thereafter**

The Genomic Prevalence Score is a machine learning platform that was trained on genomic data from 34,352 cases and transcriptomic data on more than 11,000 cases. In a validation set of more than 12,000 cases, GPS accurately predicted the cancer category in the labeled data set with an accuracy of over 93%. The accuracy increased to 97% when the second highest ranking predicted cancer type was included. The profile has been validated to differentiate among 21 different cancer types.

To order or learn more, visit **www.CarisMolecularIntelligence.com.**
US: 888.979.8669 | CustomerSupport@CarisLS.com
Intl: 00 41 21 533 53 00 | InternationalSupport@CarisLS.com